Biomarkers for Outcome in Metastatic Melanoma in First Line Treatment with Immune Checkpoint Inhibitors

Introduction: A high proportion of metastatic melanoma patients do not respond to immune checkpoint inhibitors (ICI), and until now, no validated biomarkers for response and survival have been known. Methods: We performed a retrospective analysis of outcomes in patients with metastatic melanoma trea...

Descripción completa

Detalles Bibliográficos
Autores principales: Mesti, Tanja, Grašič Kuhar, Cvetka, Ocvirk, Janja
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10044937/
https://www.ncbi.nlm.nih.gov/pubmed/36979727
http://dx.doi.org/10.3390/biomedicines11030749

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10044937/
https://www.ncbi.nlm.nih.gov/pubmed/36979727
http://dx.doi.org/10.3390/biomedicines11030749

Ejemplares similares